Nuo Therapeutics, Inc. is a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape. The Company’s Aurix System is a biodynamic hematogel that harnesses a patient’s innate regenerative abilities for the management of a variety of wounds.
Company profile
Ticker
AURX
Exchange
Website
CEO
David Emerson Jorden
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Nuo Therapeutics, Inc, CYTOMEDIX INC, AUTOLOGOUS WOUND THERAPY INC
SEC CIK
Corporate docs
Subsidiaries
Aldagen, Inc. ...
IRS number
232958959
AURX stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
19 Apr 24
8-K
Regulation FD Disclosure
16 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
D
$962.50 k in equity, sold $962.50 k, 9 investors
22 Dec 23
8-K
Entry into a Material Definitive Agreement
20 Dec 23
10-Q
2023 Q3
Quarterly report
20 Nov 23
NT 10-Q
Notice of late quarterly filing
15 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
D
$1.04 mm in equity, sold $1.04 mm, 9 investors
8 Aug 23
8-K
Entry into a Material Definitive Agreement
3 Aug 23
Latest ownership filings
SC 13G
Jacobs Paul Anthony
14 Feb 24
SC 13G/A
Flynn James E
12 Feb 24
SC 13D/A
Pittman Scott M.
20 Dec 23
4
CHARLES E SHEEDY
20 Dec 23
4
PETER CLAUSEN
20 Dec 23
4
Scott M. Pittman
20 Dec 23
4
CHARLES E SHEEDY
4 Aug 23
4
PETER CLAUSEN
3 Aug 23
4
Scott M. Pittman
3 Aug 23
4
DAVID EMERSON JORDEN
14 Nov 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 637.59 k | 637.59 k | 637.59 k | 637.59 k | 637.59 k | 637.59 k |
Cash burn (monthly) | (no burn) | 191.25 k | 263.18 k | 289.94 k | 264.96 k | 276.51 k |
Cash used (since last report) | n/a | 1.30 mm | 1.80 mm | 1.98 mm | 1.81 mm | 1.89 mm |
Cash remaining | n/a | -666.81 k | -1.16 mm | -1.34 mm | -1.17 mm | -1.25 mm |
Runway (months of cash) | n/a | -3.5 | -4.4 | -4.6 | -4.4 | -4.5 |
Institutional ownership, Q3 2023
6.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 2.70 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Flynn James E | 2.70 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Dec 23 | Pittman Scott M. | Common Stock | Grant | Acquire A | No | No | 0.5 | 600,000 | 300.00 k | 5,043,345 |
19 Dec 23 | Peter Clausen | Common Stock | Grant | Acquire A | No | No | 0.5 | 20,000 | 10.00 k | 571,201 |
19 Dec 23 | Sheedy Charles E | Common Stock | Buy | Acquire P | No | No | 0.5 | 150,000 | 75.00 k | 11,212,500 |
1 Aug 23 | Peter Clausen | Common Stock | Grant | Acquire A | No | No | 2 | 25,000 | 50.00 k | 551,201 |
1 Aug 23 | Pittman Scott M. | Common Stock | Grant | Acquire A | No | No | 2 | 100,000 | 200.00 k | 4,443,345 |